2. Signaling Pathways
  3. Anti-infection
    Metabolic Enzyme/Protease
  4. HCV Protease

HCV Protease

HCV Protease

Related Products

PDF 0.2 MB

HCV NS3-4A serine protease is a complex composed of NS3 and its cofactor NS4A. It harbours serine protease as well as NTPase/RNA helicase activities and is essential for viral polyprotein processing, RNA replication and virion formation.

The HCV NS3/4A protease efficiently cleaves and inactivates two important signaling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce interferons (IFNs), i.e., mitochondrial antiviral signaling protein (MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF). HCV infection is associated with chronic liver disease, including hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma. The NS3-4A serine protease of HCV has been one of the most attractive targets for developing specific antiviral agents against HCV.

HCV Protease Related Products (85):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N7542
    Praeroside II
    		Inhibitor
    Praeroside II is an angular-type pyranocoumarm glycoside. Praeroside II can be isolated from the n-butanol-extracts of P. praeruptorum Dunn. Praeroside II can be used for pharmacological study.
    Praeroside II
  • HY-146126
    NS5A-IN-4
    		Inhibitor
    NS5A-IN-4 (Compound 1.12) is an orally active pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with IC50 values of 1.2, 2296, 4.6, 362, 10.3 and 693 pM against gT1b, gT1a, gT2a, gT3a, gT4a and gT5a. NS5A-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-4
  • HY-N7672
    Isoeuphorbetin
    		Inhibitor
    Isoeuphorbetin, a dimeric coumarin isolated from Viola philippica, is a potent HCV protease inhibitor with an IC50 of 3.63 µg/mL.
    Isoeuphorbetin
  • HY-P4040
    Ac-D-DGla-LI-Cha-C
    		Inhibitor
    Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.
    Ac-D-DGla-LI-Cha-C
  • HY-15256S
    Faldaprevir-d6
    		Inhibitor
    Faldaprevir-d6 is deuterium labeled Faldaprevir.
    Faldaprevir-d<sub>6</sub>
  • HY-10242
    Ciluprevir
    		Inhibitor 98.08%
    Ciluprevir (BILN 2061; BILN 2061ZW) is an orally active macrocyclic peptide inhibitor of hepatitis C virus (HCV)NS3 protease, with an IC50 of 3 nM. Ciluprevir has Kᵢ values of 0.66 nM and 0.30 nM against genotypes 1b and 1a, respectively. Ciluprevir inhibits HCV RNA replication with an EC50 of 1.2 nM, and its EC50 values against genotypes 1b and 1a are 3 nM and 4 nM, respectively. Ciluprevir shows no significant inhibition against human leukocyte elastase and hepatic cathepsin B. Ciluprevir can be used for genotype 1 HCV infection.
    Ciluprevir
  • HY-145375
    NS5A-IN-1
    		Inhibitor
    NS5A-IN-1 is a proagent of the HCV NS5A inhibitor Pibrentasvir (ABT-530).
    NS5A-IN-1
  • HY-P10657
    Ac-DEMEEC-OH
    		Inhibitor
    Ac-DEMEEC-OH is a HCV NS3 protease competitive inhibitor (Ki: 0.6 µM).
    Ac-DEMEEC-OH
  • HY-15298C
    Grazoprevir sodium salt
    		Inhibitor
    Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir sodium salt inhibits SARS-CoV-2 3CLpro activity.
    Grazoprevir sodium salt
  • HY-19932
    MK-2748
    		Inhibitor
    MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection.
    MK-2748
  • HY-108029
    Deldeprevir sodium
    		Inhibitor
    Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C.
    Deldeprevir sodium
  • HY-108060AR
    Valopicitabine dihydrochloride (Standard)
    		Inhibitor
    Valopicitabine dihydrochloride (Standard) is the analytical standard of Valopicitabine (dihydrochloride) (HY-108060A). This product is intended for research and analytical applications. Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination.
    Valopicitabine dihydrochloride (Standard)
  • HY-17634R
    Glecaprevir (Standard)
    		Inhibitor
    Glecaprevir (Standard) is the analytical standard of Glecaprevir. This product is intended for research and analytical applications. Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM.
    Glecaprevir (Standard)
  • HY-167293
    Deldeprevir
    		Inhibitor
    Deldeprevir (ACH-2684) is a HCV NS3 protease inhibitor. Deldeprevir has potent antiviral activities against different genotypes and against known resistant variants (such as R155, Al56 and D168) by the formation a highly stable complex with NS3 prolease. Deldeprevir can be used for Hepatitis C virus infection research.
    Deldeprevir
  • HY-12594R
    Paritaprevir (Standard)
    		Inhibitor
    Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor).
    Paritaprevir (Standard)
  • HY-10241R
    Simeprevir (Standard)
    		Inhibitor
    Simeprevir (Standard) is the analytical standard of Simeprevir (HY-10241). This product is intended for research and analytical applications. Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses.
    Simeprevir (Standard)
  • HY-128306
    HCV-IN-50
    		Inhibitor
    HCV-IN-50 (Compound 2) is a competitive and selective HCV NS5B RNA-dependent RNA polymerase inhibitor with an IC50 of 0.3  μM for NS5B △C21 enzyme over △C55 enzyme. HCV-IN-50 has an antiviral activity and efficiently blocks replication of HCV subgenomic replicons especially mutant replicons.
    HCV-IN-50
  • HY-10237R
    Boceprevir (Standard)
    		Inhibitor
    Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 3CLpro activity.
    Boceprevir (Standard)
  • HY-16773
    Vedroprevir
    		Inhibitor
    Vedroprevir (GS-9451) is an inhibitor for HCV NS3/4A protease with an IC50 of 3.2 nM. Vedroprevir is also an inhibitor for breast cancer resistant protein (BCRP) with an IC50 of 1.4 μM. Vedroprevir inhibits P-gp, MRP1 and MRP2 with IC50 of 34, 14.9 and 12 μM, respectively. Vedroprevir exhibits good pharmacokinetic characteristics in rats and dogs.
    Vedroprevir
  • HY-117802
    CID-50930756
    		Inhibitor
    CID-50930756 is an HCV NS3 helicase inhibitor with an IC50 of 22 μM.CID-50930756 inhibits HCV NS3 helicase-catalyzed nucleic acid unwinding.CID-50930756 inhibits HCV replication in hepatoma cells harboring a stably transfected subgenomic HCV replicon.CID-50930756 does not exhibit toxicity to hepatoma cells at 10 μM.CID-50930756 shows weak DNA-binding activity, displacing less than 20% of SYBR Green I from DNA at 100 μM.CID-50930756 can be used for the research of hepatitis c.
    CID-50930756